Labeling Requirements for
Human Prescription Drug and Biological Products
Revision of a currently approved collection
No
Regular
01/31/2025
Requested
Previously Approved
36 Months From Approved
01/31/2025
433,324
433,323
1,913,896
1,913,864
0
129,150
The information collection supports
agency regulations governing the content and format of labeling for
human prescription drug and biological products. Respondents to the
collection are sponsors of new drug and biological product
applications.
The information collection
reflects nominal adjustments that include the addition of one
response and 32 hours annually, and we have removed costs
previously attributable to respondents publicly posting safety
labeling changes which we believe is now usual and customary
practice. At the same time, we have clarified the scope of activity
announcing in our notice OMB approved-modifications since last
review (changes approving the addition of recommendations found in
guidance; burden associated with Strategic National Stockpile
labeling; bar code exemptions; and hypertension claims) and invited
public comment. Although no comments were received as discussed in
Q-8, we characterized the renewal request as a revision.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.